More than 2.5 million people work night-shifts. In 2007, the International Agency for Research on Cancer (IARC) reported that working shifts generally disturbs momentum classified as being “probably carcinogenic to humans”.
A shocking report revealed that an error in breast cancer screening tests may have affected a vast number of women across England. Due to a computer algorithm failure dating back to 2009, a group of women was not sent for routine breast cancer screening tests before their 71st birthdays. Public Health England (PHE) predicted that around 450,000 women may have been affected due to these screening errors during 2009.
Breast Cancer appears when unusual cells start growing in breast tissue and can affect both women and men. It was estimated that in the U.S. alone there will be a total of 330,080 new cases of breast cancer in women and about 2,550 in men by the end of 2018.
At present, breast cancer patients need to wait for nearly two to three months to find out via a scan whether palbociclib is working. This new test could detect the circulating tumor DNA which enters the bloodstream. By measuring and comparing PIK3CA levels in a blood test before and 15 post palbociclib therapy, one could predict the effectiveness of the drug.
The amazing discovery under the authorship of Professor Chenfang Dong from the Zhejiang University School of Medicine in Hangzhou, China revealed that the widely used osteoporosis drug named zoledronic acid, inhibits UGT8 activity directly, which led to the prevention of basal-like breast cancer.
AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) today presented data from the Phase III OlympiAD trial, showing the final overall survival (OS) results for LYNPARZA®(olaparib) in metastatic breast cancer at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, April 14-18, 2018.
Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced publication of an article that demonstrated the Company’s proprietary ADAPT Biotargeting System™ (ADAPT) significantly out-performed standard HER2 testing in predicting response to trastuzumab (Herceptin®) for breast cancer patients.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.